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Abstract: Alzheimer’s disease is a neurodegenerative disorder that affects
mostly the elderly. The main histopathological markers are the senile plaques
formed by amyloid-β peptide (Aβ) aggregates that can perforate the plasma
membrane of cells, increasing the intracellular calcium levels and releasing
synaptic vesicles that finally lead to a delayed synaptic failure. Several
membrane proteins and lipids interact with Aβ affecting its toxicity in neurons.
Here, we focus on NMDA receptors (NMDARs) as proteins that could be
modulating the association and neurotoxic perforation induced by Aβ on the
plasma membrane. In fact, our results showed that decreasing NMDARs,
using enzymatic or siRNA approaches, increased the association of Aβ to the
neurons. Furthermore, overexpression of NMDARs also resulted in an
enhanced association between NMDA and Aβ. Functionally, the reduction in
membrane NMDARs augmented the process of membrane perforation. On the
other hand, overexpressing NMDARs had a protective effect because Aβ was
now unable to cause membrane perforation, suggesting a complex
relationship between Aβ and NMDARs. Because previous studies have
recognized that Aβ oligomers are able to increase membrane permeability and
produce amyloid pores, the present study supports the conclusion that
NMDARs play a critical protective role on Aβ actions in hippocampal neurons.
These results could explain the lack of correlation between brain Aβ burden
and clinically observed dementia.
Keywords: Alzheimer’s disease, amyloid-beta, glutamate, glycine receptor,
hippocampal neurons, membrane damage, membrane pore, NMDA receptor

Introduction
Alzheimer’s disease (AD) is the most prevalent
neurodegenerative disorder in the elderly [1]. AD manifests
progressively with cognitive and behavioral impairments [2]
characterized by loss of memory and learning [3]. One of the major
histopathological markers of AD are the senile plaques formed by
amyloid-β peptide (Aβ) aggregates [4]. These Aβ aggregates produce
a complex cascade of eventsthat finally lead to synaptic failure and
neuronal death [5].
A common hypothesis used to explain the toxicity induced by Aβ
is the formation of amyloid pores in the plasma membrane. Regarding
this, several studies from our and other laboratories support the notion
that membrane disruptions are induced by Aβ [6–13]. Furthermore, Aβ
perforation allows the entry of small molecules and ions, such as
calcium, into the cells [6, 7, 12]. This sustained calcium influx
increases the release in synaptic vesicles, leading to a delayed
synaptic failure produced by vesicle depletion [6–8].
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It is now believed that Aβ association and toxic actions at the
membrane level can be affected by the lipid and protein composition
[9, 12, 14–18].N-methyl-D-aspartate receptors (NMDARs) are excitatory ligand gated ion channels that have been described as
important for some of the toxic effects induced by Aβ, similar to that
observed with other membrane proteins like cellular prion, mGluR5,
nicotinic receptor, and AβPP [9, 19–25]. The glutamate NMDA receptor
is a tetramer composed of different subunit combinations (NR1, NR2AD) allowing the influx of Na+ and Ca2 + ions into the neurons resulting
in excitation [26, 27]. The relationship between AD and NMDARs is
widely postulated [28, 29], but the mechanisms involving this
relationship are not fully understood.
One of the strongest evidence for the clinical relevance of such
interactions between Aβ and NMDARs in AD is that the NMDA receptor
antagonist, memantine, is used clinically in the treatment of AD [28].
In fact, other NMDAR antagonists, like (+)MK-801, or the removal of
extracellular Ca2 +, reduced Aβ1–40-induced Ca2 + transients, NO
production and neurotoxicity in cultured neuroblastoma cells [30].
Moreover, (+) MK-801 partially prevented the decrease in cell viability
and the energy impairment induced by Aβ1–42 in HEK293 cells
transiently expressing NR1/NR2A or NR1/NR2B subunits [29].
Regarding a potential interaction between Aβ and NMDAR, the
data is controversial. While some authors indicate that the coimmunoprecipitation of Aβ dodecameric oligomers with NR1 and NR2A
is evidence for their interaction [31], others have failed to detect
binding of Aβ1–42 to any known regulatory sites on glutamate receptors
[28]. Furthermore, recent data indicates that such effects of Aβ1–42 on
NMDA receptors may be due to its binding to postsynaptic anchoring
proteins such as PSD-95 or other membrane proteins like prion [21,
32, 33].
Here, in an attempt to clarify a potential role of NMDARs on Aβ1–
42-induced neurotoxicity, we examined the ability of the peptide to
associate to and disrupt plasma membranes, something that has not
been studied until now. The results indicate that NMDARs are an
important factor controlling Aβ neurotoxicity.
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Materials and Methods
Primary cultures of rat hippocampal neurons
Hippocampal neurons were obtained from 18-day pregnant
Sprague-Dawley rats and maintained for10-14 days in vitro (DIV) as
previously described [34]. All animals were handled in strict
accordance with NIH guidelines and approved by the Ethics Committee
of the Universidad de Concepción (Concepción, Chile).

Peptide preparation and storage
Human Aβ1–42 labeled with FAM (green fluorescence, Aβ-FAM) at
its N-terminus, and unlabeled peptides were purchased from Anaspec
(CA, USA). The preparation and storage were performed as previously
reported by our lab [6]. Briefly, Aβ1–42 was dissolved in DMSO
(10 mg/ml) and stored in aliquots at –20°C. To prepare Aβ oligomers
(80 μM), aliquots of the peptide (250 μg in 25 μl of DMSO) were added
to 700 μl of PBS (Gibco, USA) and vertically agitated (200 RPM at
37°C) for 90 min and stored at 4°C until use. Aβ-FAM was dissolved in
DMSO (4 mg/ml) and immediately stored in aliquots at –20°C.

Transfection
Neuronal transfection was performed using magnetofection with
the reagent Neuromag as described by the protocol provided by the
manufacturer (Oz Biosciences, France). To decrease the levels of
NMDARs, siRNAs for NR1 and NR2B were co-transfected with GFP (2
μg total) to visualize the transfected neurons.
To increase the levels of NMDARs, HEK cells were transfected
with the plasmids NR1, NR2B and GFP (2 μg total) using lipofectamine
2000 (Invitrogen, USA) following the manufacturer’s instructions. The
plasmids and siRNAs used in this study were previously described [35,
36].
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Electrophysiology
Electrophysiological recordings were carried out using the patch
clamp technique as previously described [8, 37]. Briefly, culture media
was changed for an external solution containing (in mM): 150 NaCl,
5.4 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 glucose and 10 HEPES (pH 7.4). The
internal solution consisted of (in mM): 120 KCl, 2.0 MgCl2, 2 ATP-Na2,
10 BAPTA, 0.5 GTP, 10 HEPES (pH 7.4). The holding potential was
fixed at –60 mV and currents were acquired using a Digidata 1200
board and the pClamp10 software (Axon Instruments, Inc.). Recording
pipettes were pulled from borosilicate glass (WPI, Sarasota, FL) on a
horizontal puller (Sutter Instruments, Novato, CA) having a
resistancebetween 5 and 10 MΩ. Perforated recordings were obtained
as previously described [6, 8]. Briefly, Aβ was added to the pipette
internal solution and a 5 mV pulse was used to monitor the perforation
in cell attached configuration. For evoked current recordings, the
experiments were performed at room temperature (20–25°C) using a
membrane potential of –60 mV. Data are given as mean±S.E.M. and
were obtained from more than 5 experiments. Recordings were
performed in the presence of 100 nM TTX (tetrodotoxin) to inhibit
action potentials.

Immunocytochemistry
Experiments were performed as previously described [9]. The
primary antibodies used for 16 hwere: anti-MAP2, 1 : 400 (Santa Cruz
Biotechnology, CA, USA); and NR2B, 1 : 200 (Covance, USA). The
secondary antibodies conjugated withFITC
(ExMax/EmMax = 500/517 nm), Cy3 (ExMax/EmMax = 545/570 nm), or
Cy5 (ExMax/EmMax= 649/670 nm) (1 : 400, Jackson ImmunoResearch
Laboratories, USA) were incubated for 2 h for fluorescent staining.
Finally, samples were mounted in fluorescent mounting medium
(DAKO, CA, USA) and images were obtained using a Nikon Eclipse
confocal microscope (Nikon, Japan). The immunoreactivity of the
proteins was quantified at primary processes with ImageJ software
(NIH). Fluorescent signal was quantified as relative units (RU) using a
region of interest (ROI).
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Western blots
Equal amounts of proteins were separated on 10–12% SDSPAGE gels as previously described [7, 8]. Protein bands were
transferred onto nitrocellulose membranes, blocked with 5% milk, and
incubated with the primary antibody anti-NR2B (1 : 1000; Covance,
USA) or α-tubulin (Sigma, USA). Immunoreactive bands were detected
with secondary antibodies conjugated with HRP 1 : 5000 (Santa Cruz
Biotechnology, CA, USA) and visualized with ECL Plus Western Blotting
Detection System (PerkinElmer, MA, USA).

Data analysis
Non-lineal analysis was performed using Prism (Graph Pad). The
analysis of the cluster size, number, and fluorescence intensity were
performed using the ImageJ software package (NIH, USA) and using
appropriate and similar intensity thresholds for cluster resolution.
Membrane charge was analyzed by integrating the transient
capacitative current after subtracting the pipette capacitance. The
values are expressed as mean±SEM (standard error mean). Statistical
differences were determined using Student’s t test or ANOVA. The
experiments were performed in triplicate.

Results
We wanted to evaluate the potential role of NMDARs in the
mechanism of Aβ1–42 association and perforation of the plasma
membrane. Therefore, we used experimental protocols that could
either decrease or increase the levels of NMDARs in the cell membrane
before performing the assays. First, we used a mild enzymatic
proteolytic digestion using trypsin (0.00025%, 30 min), a serine
protease widely used to remove membrane proteins [38, 39], thus
decreasing the levels of NMDARs in the membrane of hippocampal
neurons as detected by immunocytochemistry against the NR2B
subunit of the receptor (Fig. 1A). More detailed analyses of the
immunofluorescence data showed that treatment of hippocampal
neurons with trypsin decreased the NMDAR puncta number in primary
neuronal processes (Fig. 1B). For instance, control values were 12±1.2
punctas, and these values decreased to 6±1.10 punctas with the
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treatment. This result is in agreement with western blot analyses that
also showed a decrease of 60±12% in NMDAR total levels after the
treatment as compared to control (Fig. 1 C,D). To evaluate if the
treatment was actually reducing functional membrane NMDAR in the
neurons treated with trypsin for 30 min, we performed
electrophysiological recordings using patch clamp techniques. The
neurons were stimulated with a large concentration of NMDA (100 μM)
resulting in current amplitudes of several hundred pA. The results
clearly showed a significant reduction in the amplitude of the NMDAevoked current in trypsin-treated neurons (approximately 20%) as
compared to the control condition (Fig. 1E). An internal control using
the NMDAR antagonist, D-AP5 (100 μM), showed that the NMDAevoked current was completely blocked by D-AP5, indicating that the
evoked current was only mediated by NMDARs (Fig. 1E). As expected,
the NMDA current density (pA/pF) was also significantly lowered in
trypsin-treated neurons (4.4 ± 2 pA/pF)as compared to control cells
(20 ± 2 pA/pF) (Fig. 1F). No differences were found in the values of
membrane capacitance indicating that the treatment did not affect the
size of the neurons (Fig. 1G). These data demonstrate that the use of
a very low concentration of trypsin (0.00025%) is sufficient to
decrease NMDAR levels in the neuronal membrane, making this
experimental protocol a good tool for further assays which need
decreased levels of this ion channel receptor.
The next step was to evaluate the degree of association of
oligomeric Aβ1–42 in control and trypsin treated neurons. Figure 2
shows a confocal micrograph of NR2B (red) and MAP2 (blue) together
with the fluorescent signal of Aβ (1 h incubation with Aβ1–42 coupled to
FAM, a green fluorescent tag)in control and trypsin-treated cells. The
overall analysis of this data shows that after treating the hippocampal
neurons with trypsin, the NR2B signal was reduced and that of Aβ
increased (Fig. 2A). The measurement of Aβ clusters in primary
neurites corroborated the increase in Aβ-FAM association together with
a decrease in NMDAR on trypsin-treated neurons (Fig. 2B). A more
detailed analysis indicated that the Aβ-associated clusters were much
larger after the treatment (Fig. 2C). In fact, trypsin-treated neurons
resulted in an increase in the size of Aβ-FAM clusters together with the
number of big clusters (Fig. 2C,D).
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Furthermore, to characterize the role of NMDARs in Aβ
association using more specific methodologies, we used siRNA for
NMDAR subunits NR1 and NR2B to selectively decrease the NMDAR
levels in these hippocampal neurons. Neuronal transfections for 48 h
with siRNAs also reduced the amplitude of NMDA-evoked currents (100
μM) in patch clamp recordings (Fig. 3A). For instance, the data show
that treatment with the siRNA decreased the amplitude of the NMDA
current from 720 ± 96 to 347 ± 63 pA (Fig. 3B), resulting in a
reduction of approximately 48%. After confirming that the siRNA
reduced the expression of membrane NMDARs, we incubated the
neurons for 1 h with Aβ-FAM to assess the association to the neuronal
membrane (Fig. 3C). The data obtained with immunocytochemistry
showed that the siRNA-transfected neurons had an increase in Aβ-FAM
association, incrementing the puncta number and the intensity of AβFAM signal in primary processes (Fig. 3D,E), similar to the results
obtained in trypsin-treated neurons.
Previous studies have shown that following Aβ association to the
plasma membrane, a process of membrane damage begins that
produces an increase in membrane current (perforation) and
intracellular calcium levels which lead to a delayed synaptic failure [6–
8, 40]. Thus, the increase in membrane association of Aβ1–42 to
neurons depleted of membrane NMDARs could result in an increase in
membrane damage. To determine if this was actually occurring, we
performed electrophysiological experiments using perforated patch
clamp recordings, as previously described [6, 8, 41] (see methods),
and found that Aβ1–42 increased the peak and charge of the
capacitative current after 15 minutes of application in control neurons
(Fig. 4A). The effect of Aβ1–42 on the amplitude of the capacitative
current, on the other hand, developed much quicker in neurons
previously treated with trypsin to reduce NMDAR (Fig. 4A). The
treatment, however, did not have any effect on the holding current.
The time course of Aβ1–42 effects on membrane charge in control and
after trypsin shows that the treatment caused an increase in the
perforation onset (Fig. 4B). Data show that the approximate t1/2 of Aβ
effect on the perforation was 24 min in control conditions and reduced
to 17 min with the treatment. Furthermore, the analysis of the time to
acquire an open configuration (perforation) in control and trypsintreated neurons showed that the effect of Aβ1–42 was concentrationdependent, with faster effects at higher concentrations (Fig. 4C). The
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latter suggests that removal of membrane proteins, such as NMDARs,
facilitates the membrane perforation induced by Aβ1–42.
Next, we examined if increasing NMDARs in the cell membrane
could have the opposite effect, thus increasing the association of Aβ
and the consequent perforation of the membrane. Thus, we
overexpressed and electrophysiologically characterizedthe NMDAR
subunits NR1 and NR2B in HEK cells (Fig. 5A), and glycine receptor as
a control (Fig. 5B), evaluating the association of Aβ-FAM after 1 h
incubation (Fig. 5C). Data showed that the Aβ-FAM association
increased in the cells that overexpressed NMDARs, resulting in a
reduced distance between the Aβ-FAM clusters (Control 0.55 ± 0.03,
NMDA-R 0.24 ± 0.01 pixels) and an increase in their size (Control 0.46
± 0.05, NMDA-R 0.97 ± 0.04 μm) (Fig. 5B,C), which is similar to that
observed when the levels of NMDARs were decreased (Figs. 2, 3). On
the other hand, overexpression of another membrane protein that is
associated to inhibitory transmission, the glycine receptor (GlyR), did
not produce any change in Aβ-FAM association to the plasma
membrane indicating that the effect was selective for NMDARs (Fig. 5).
Thereafter, we evaluated the membrane perforation induced by Aβ1–
42in cells overexpressing NMDARs or GlyRs (Fig. 6A). The data
obtained showed that NMDAR overexpression blocked the membrane
perforation induced by Aβ1–42, while overexpression of GlyR was unable
to affect the membrane charge transferred (Control 12.3 ± 5.3, Aβ
155.3 ± 14.3, NMDAR 25.4 ± 4.8, GlyRα1 135.9 ± 13.8 fC) (Fig. 6B).
As a positive control for membrane perforation, we used a small
peptide constructed with the native sequence of Aβ11–17 that includes
the two histidine residues 13 and 14 (EVHHQKL) [42] which blocked
the perforation of the membrane induced by Aβ (Fig. 6B) [6, 41, 42].
The latter suggests that NMDAR presence in the membrane of the cells
increases Aβ association but interferes with the perforation induced by
the peptide.

Discussion
The presence of a direct or indirect interaction between Aβ and
NMDARs is still under discussion, however, the role of NMDARs in AD is
becoming more recognized [28]. Previous studies, for example, are
focused on the use of NMDAR antagonists, like memantine or (+) MK-
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801 as AD treatments [29, 30]. In fact, memantine is one of the few
FDA approved drugs for AD [43, 44].
In the present study, we characterized a largely unexplored area
of the NMDAR relationship with Aβ regarding membrane association
and subsequent perforation and that might have clinical implications.
The original idea was to evaluate if the association of Aβ to the plasma
membrane was affected by altering the levels of functional NMDARs,
thus, cells were treated with trypsin to reduce receptor levels, or
transfected with plasmids containing NMDAR subunits to increase the
receptor levels. Interestingly, both treatments resulted in higher
association of Aβ to the cells, suggesting a more complex role of
NMDARs than expected. A simple way of explaining these results of Aβ
association is what we call the “forest effect”, where the membrane
proteins can be likened to trees covering the ground (lipids) (Fig. 7).
Thus, decreasing the level of NMDARs, suggested to be important for
the interaction of Aβ with the neuronal membrane [21, 31], might be
facilitating its association to lipids previously not accessible, resulting
in enhanced clustering (Figs. 2 and 3). On the other hand, the increase
in Aβ association after the overexpression of NMDARs might be due to
enhanced direct or indirect interactions with these excitatory
receptors. In agreement, it is now believed that Aβ has promiscuous
membrane interactions associating to cellular prion, nicotinic
receptors, AβPP, and lipids like GM1 and cholesterol, thus affecting Aβ
clustering [9, 15, 17, 19–25]. Therefore, the increased Aβ association
after overexpression of NMDARs could be explained by the formation
of Aβ/NMDAR complexes [20, 31]. Interestingly, this effect was
specific for NMDARs since overexpression of GlyRs did not affect Aβ
association to the membrane. This differential effect might be relevant
for the disease because GlyRs, unlike NMDARs, are inhibitory proteins
that are mainly expressed in spinal cord neurons [45, 46], which are
believed to be largely unaffected by the disease.
Interestingly, although decreasing or increasing NMDARs
resulted in similar increases in Aβ association to the membrane
(clustering), our data showed that the functional impact of altering the
levels of NMDARs in the membrane was quite different. For instance,
decreasing NMDARs resulted in an accelerated rate of brain membrane
damage revealed as an increase in membrane current in the presence
of Aβ. This is remarkable because it demonstrates differences on the
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impact that Aβ association has on the plasma membrane. One
plausible explanation is that the fine-tuning of Aβ interaction with
membrane lipids and proteins affects its capacity to form amyloid
pores. Thus, a membrane devoid of some types of proteins (i.e.,
NMDARs) might be more sensitive to Aβ-induced damage. It was
reported that increasing protein levels in the membrane produced a
reduction on its fluidity [47], thus our results might also be explained
by a reduced level of membrane fluidity. Nevertheless, lipid rafts can
also regulate Aβ association to the membrane [15, 17, 18]. For
instance, cholesterol in lipid rafts can affect Aβ association and
membrane damage by decreasing membrane fluidity as a consequence
of reduced phospholipid movement in the bilayer [17, 48].
On the other hand, we found that the decrease in NMDAR levels
by siRNAs or trypsin also increased Aβ association. In parallel, the
perforation of the membrane was faster when compared to control
cells (Fig. 5). We believe that by decreasing the levels of NMDARs, Aβ
associates preferentially to membrane lipids facilitating the process of
perforation [15, 16, 49]. For example, it is believed that GM1 mediates
Aβ association, seeding, fibrillogenesis and membrane disruption [15,
49]. These results could very well explain why some people with high
levels of Aβ in the brain do not show dementia and vice versa. In other
words, some proteins might be buffering the levels of toxic Aβ [50].
In conclusion, our data support the role of NMDARs as an
important mediator for Aβ association and damage/perforation in the
plasma memb-rane, actively participating in the membrane toxicity
induced by Aβ. These results could explain the lack of correlation
between brain Aβ burden and clinically observed dementia.
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Figures and Tables
Fig. 1. Treatment with trypsin decreased NMDARs in hippocampal neurons. A)
Microphotograph shows NMDAR (NR2B, red) in neuronal primary processes of cultures
treated without or with trypsin (0.00025%, 30 min). B) Quantification of NMDAR
puncta number shows a decrease in trypsin-treated neurons (0.00025%, 30 min)
versus control (not treated). C) Western blot showing the levels of NR2B in control and
trypsin-treated neurons (0.00025%, 30 min). α-tubulin was used as a loading control.
D) Quantification of NR2B levels from the western blot in control and treated neurons.
E) Representative evoked currents using NMDA (100 μM) and NMDA plus D-AP5 (100
μM) in control neurons and pre-treatment with trypsin 0.00025% for 30 min. Black bar
represents the time of perfusion. F) Plot of current density (pA/pF) in control and
trypsin pre-treated neurons showing the current decrease in trypsin-treated neurons.
G) The graph shows the capacitance (pF) in control and trypsin-treated cells.
**p < 0.01; ***p < 0.001.
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Fig. 2. Trypsin treatment decreased NMDARs and increased Aβ association in
hippocampal neurons. A) Immunofluorescence microphotograph showing the
association of Aβ-FAM (1 μM, 1 h) to hippocampal neurons pre-treated with or without
trypsin (0.00025%, 30 min). NMDA receptor is shown in red (NR2B subunit), Aβ-FAM
in green and MAP2 in blue. Scale bar represents 20 μm. B) Representative images of
neuronal primary processes (10 μm) showing the levels of NMDAR (red) and the
association of Aβ-FAM (green, 1 h, 1 μM) in control and trypsin pre-treated
(0.00025%, 30 min) neurons. The panel at the right displays a zoom of the dendrite.
C) Plot shows the quantification of Aβ-FAM cluster size ( μm). D) Graph illustrates the
relationship between the number and size (nm) of Aβ-FAM clusters in control and
treated neurons. **p < 0.01.
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Fig. 3. NMDARs affect Aβ association in hippocampal neurons. A) Representative
traces of NMDA-evoked currents in control and after transfection with siRNAs geared
towards the NMDAR (NR1 and NR2B subunits). The black bar represents the time of
NMDA perfusion (100 μM). B) Plot showing the decrease in the amplitude of NMDAevoked currents for the siRNA-transfected neurons versus control. C)
Immunofluorescence showing Aβ-FAM (green) association (1 μM, 1 h) to control and
siRNA transfected neurons. MAP2 stained the neurons (blue) and mCherry was used as
a control for transfection (red). The white bottom bar represents 20 μm of length. D,
E) Plots show the Aβ-FAM puncta number and fluorescence intensity in primary
processes (20 μm) for control and transfected neurons. *p < 0.05, **p < 0.01.
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Fig. 4. Trypsin treatment decreased the time to perforated configuration induced by
Aβ. A) Representative capacitative currents (5 mV) in the perforated configuration
using Aβ (1 μM) in the pipette in HEK cells. B) Plot showing the charge transferred
through the membrane of the cell in a time dependent manner, showing that Aβ
perforates the membrane faster in trypsin pre-treated cells (0.00025%, 30 min) than
in control cells without any treatments. Arrow heads (red) indicate the times of the
recordings shown in panel A. C) Graph showing the time needed by Aβ to acquire a
perforation configuration. The trypsin pre-treated cells had a faster perforation time.
*p < 0.05, **p < 0.01.
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Fig. 5. NMDAR overexpression increased Aβ-FAM clustering in HEK cells. A) The trace
shows NMDA-evoked current in HEK cells transfected with NR1 and NR2B. B) The trace
shows a glycine evoked current in HEK cells transfected with the alpha subunit of the
glycine receptor (GlyRα1). C) Microphotograph showing Aβ-FAM association (1 μM, 1 h)
to HEK cells overexpressing NMDAR (NR1/NR2B), GlyRα1 and RFP as a control for
transfection. D) Plot showing the Aβ-FAM cluster inter-distance. E) Graph showing the
increase in Aβ-FAM cluster size in cells that overexpress NMDAR. **p < 0.01.
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Fig. 6. NMDAR overexpression inhibited the Aβ-induced membrane perforation. A)
Scheme representing the perforated patch clamp configuration used in the
experiment. Aβ is added to the patch pipette with the internal solution and the cellattached configuration is acquired. The recorded cells were previously transfected with
GFP, NMDAR or GlyRα1. B) Plot showing the membrane charge transferred (fC) in
control HEK cells and HEK cells transfected with GFP, NMDAR or GlyRα1 after 20 min in
the presence of Aβ (1 μM). The cells that overexpressed NMDARs were resistant to Aβ.
Na7, a peptide that blocks the amyloid pore, was used as a control for the Aβ
perforation. **p < 0.01, ***p < 0.001.

Fig. 7. “Forest effect” of membrane proteins involved in Aβ association and membrane
perforation. A) The increase in membrane protein levels, such as NMDAR, augments
the association of Aβ (red circles) to these proteins, decreasing the association of Aβ
to membrane lipids and therefore the perforation induced by Aβ. B) The decrease in
membrane proteins, i.e., NMDAR, results in an increase in Aβ association to the lipids
of the plasma membrane, thus increasing the perforation induced by Aβ.
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